The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
In this interview, Shambavi Richard, MD, Mount Sinai, New York City, NY, provides insight into the Phase Ib/II DURGA-1 study (NCT05850234), which is evaluating the safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in patients with relapsed/refractory (R/R) multiple myeloma (MM). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
